TW202509017A - 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途 - Google Patents

胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途 Download PDF

Info

Publication number
TW202509017A
TW202509017A TW113124586A TW113124586A TW202509017A TW 202509017 A TW202509017 A TW 202509017A TW 113124586 A TW113124586 A TW 113124586A TW 113124586 A TW113124586 A TW 113124586A TW 202509017 A TW202509017 A TW 202509017A
Authority
TW
Taiwan
Prior art keywords
amino
phenyl
nicotinamide
azabicyclo
hexane
Prior art date
Application number
TW113124586A
Other languages
English (en)
Chinese (zh)
Inventor
路卡 亞力斯塔
麥可 派翠客 狄隆
瑞妮 拉特曼
迪米崔歐斯 利卓斯
尼可勞斯 喬漢尼斯 史蒂夫
湯瑪士 優兒瑞其
佩姬 烏索曼
史文 威勒
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202509017A publication Critical patent/TW202509017A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
TW113124586A 2016-07-20 2017-07-18 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途 TW202509017A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364620P 2016-07-20 2016-07-20
US62/364,620 2016-07-20

Publications (1)

Publication Number Publication Date
TW202509017A true TW202509017A (zh) 2025-03-01

Family

ID=60991950

Family Applications (5)

Application Number Title Priority Date Filing Date
TW113124586A TW202509017A (zh) 2016-07-20 2017-07-18 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
TW106123900A TWI712598B (zh) 2016-07-20 2017-07-18 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
TW111103316A TWI806385B (zh) 2016-07-20 2017-07-18 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
TW110101592A TWI755255B (zh) 2016-07-20 2017-07-18 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
TW112118991A TWI851226B (zh) 2016-07-20 2017-07-18 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途

Family Applications After (4)

Application Number Title Priority Date Filing Date
TW106123900A TWI712598B (zh) 2016-07-20 2017-07-18 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
TW111103316A TWI806385B (zh) 2016-07-20 2017-07-18 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
TW110101592A TWI755255B (zh) 2016-07-20 2017-07-18 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
TW112118991A TWI851226B (zh) 2016-07-20 2017-07-18 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途

Country Status (26)

Country Link
US (3) US10710980B2 (enExample)
EP (3) EP4442317A3 (enExample)
JP (4) JP7030776B2 (enExample)
KR (7) KR102454129B1 (enExample)
CN (2) CN114014844B (enExample)
AR (1) AR109108A1 (enExample)
AU (5) AU2017298187B2 (enExample)
CA (1) CA3030332A1 (enExample)
CY (1) CY1124967T1 (enExample)
DK (2) DK3971177T3 (enExample)
EA (2) EA037520B1 (enExample)
ES (2) ES2984746T3 (enExample)
FI (1) FI3971177T3 (enExample)
HR (2) HRP20241015T1 (enExample)
HU (2) HUE067992T2 (enExample)
LT (2) LT3971177T (enExample)
MX (2) MX388518B (enExample)
PL (2) PL3487851T3 (enExample)
PT (2) PT3971177T (enExample)
RS (2) RS62819B1 (enExample)
RU (1) RU2747318C2 (enExample)
SI (2) SI3487851T1 (enExample)
SM (2) SMT202100723T1 (enExample)
TW (5) TW202509017A (enExample)
UY (1) UY37331A (enExample)
WO (1) WO2018014829A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3971177T3 (da) * 2016-07-20 2024-07-15 Novartis Ag Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer
CN115038443A (zh) 2019-11-22 2022-09-09 因西特公司 包含alk2抑制剂和jak2抑制剂的组合疗法
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
WO2021257532A1 (en) * 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CN116478145B (zh) * 2022-04-13 2024-02-02 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
AU683431B2 (en) 1992-11-17 1997-11-13 Ludwig Institute For Cancer Research Activin receptor-like kinases, proteins having serine/ threonine kinase domains and their use
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6914058B2 (en) * 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2007521252A (ja) 2003-04-11 2007-08-02 エスジーエックス ファーマシューティカルズ，インコーポレイティド 化合物ライブラリーおよび薬剤発見方法
BRPI0511571A (pt) 2004-05-27 2008-01-02 Pfizer derivados de aminopiridina como agonistas de dopamina d3 seletivos
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
RU2007141401A (ru) 2005-04-08 2009-05-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Терапевтический агент для лечения дискинезии
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
PE20071240A1 (es) * 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
WO2007123896A2 (en) 2006-04-18 2007-11-01 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodyplasia ossificans progressiva (fop)
WO2008002671A2 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
WO2008030611A2 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
EP2062048A4 (en) 2006-09-12 2009-12-02 Gen Hospital Corp METHOD FOR IDENTIFYING CELL SIGNALING MODULATING COMPOUNDS AND METHOD FOR USING SUCH COMPOSITES
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
AU2009271414A1 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl GPR119 agonists and uses thereof
PH12013500294A1 (en) 2010-08-20 2017-08-23 Wyeth Llc Designer osteogenic proteins
RU2013130907A (ru) 2010-12-06 2015-01-20 Пирамал Энтерпрайзис Лимитед Замещенные имидазохинолиновые производные
WO2012087938A1 (en) 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
PL2714677T3 (pl) 2011-05-23 2019-02-28 Merck Patent Gmbh Pochodne pirydynowe i pirazynowe
BR122019017259B1 (pt) 2011-09-09 2022-05-10 Lantheus Medical Imaging, Inc Compostos úteis como agentes de imageamento, composições que os compreende, métodos, e uso de agentes de imageamento
CA2886187C (en) 2012-09-28 2020-04-14 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
WO2014138088A1 (en) 2013-03-04 2014-09-12 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
DK2970205T3 (da) * 2013-03-14 2019-07-29 Tolero Pharmaceuticals Inc JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
TR201911140T4 (tr) 2013-10-21 2019-08-21 Merck Patent Gmbh Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları.
JP6601687B2 (ja) 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
AU2016209321B2 (en) 2015-01-20 2019-05-09 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds, compositions and method of using thereof
CN108368083B (zh) 2015-08-31 2022-02-01 东亚首希控股股份有限公司 杂芳基化合物及其作为治疗性药物的用途
DK3971177T3 (da) * 2016-07-20 2024-07-15 Novartis Ag Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer
CN109478899B (zh) 2016-07-20 2021-07-27 卡文迪什动力有限公司 用于利用dvc调谐天线的方法
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation

Also Published As

Publication number Publication date
KR20230117248A (ko) 2023-08-07
FI3971177T3 (fi) 2024-07-30
EP4442317A2 (en) 2024-10-09
WO2018014829A1 (en) 2018-01-25
KR102454129B1 (ko) 2022-10-14
PL3971177T3 (pl) 2024-10-28
PT3971177T (pt) 2024-07-30
TW201805277A (zh) 2018-02-16
EP3487851A1 (en) 2019-05-29
TWI755255B (zh) 2022-02-11
KR102359707B1 (ko) 2022-02-09
RU2019104609A (ru) 2020-08-20
DK3487851T3 (da) 2021-12-20
AU2019246857B2 (en) 2020-12-24
TWI712598B (zh) 2020-12-11
KR102559539B1 (ko) 2023-07-26
TW202336011A (zh) 2023-09-16
LT3487851T (lt) 2021-12-27
EA201990343A1 (ru) 2019-06-28
JP7253086B2 (ja) 2023-04-05
SI3971177T1 (sl) 2024-10-30
MX388518B (es) 2025-03-19
AU2024205058A1 (en) 2024-08-15
BR112019000941A2 (pt) 2019-04-30
JP7584553B2 (ja) 2024-11-15
KR20240074904A (ko) 2024-05-28
LT3971177T (lt) 2024-08-26
AU2023200265A1 (en) 2023-02-16
US20210155606A1 (en) 2021-05-27
KR102281550B1 (ko) 2021-07-27
RS66041B1 (sr) 2024-11-29
CN114014844B (zh) 2024-10-01
KR102719881B1 (ko) 2024-10-23
HUE057328T2 (hu) 2022-05-28
EP3971177B1 (en) 2024-06-26
AU2021201424A1 (en) 2021-03-25
CA3030332A1 (en) 2018-01-25
EA037520B1 (ru) 2021-04-07
RU2021111037A (ru) 2021-05-13
JP2025032086A (ja) 2025-03-11
MX2019000837A (es) 2019-07-04
KR20190026917A (ko) 2019-03-13
UY37331A (es) 2018-02-28
SI3487851T1 (sl) 2022-03-31
SMT202100723T1 (it) 2022-01-10
JP2019521167A (ja) 2019-07-25
ES2984746T3 (es) 2024-10-30
JP2022078137A (ja) 2022-05-24
RU2747318C2 (ru) 2021-05-04
KR20220143770A (ko) 2022-10-25
AU2021201424B2 (en) 2022-10-20
US10710980B2 (en) 2020-07-14
AU2019246857A1 (en) 2019-10-31
EP4442317A3 (en) 2025-01-01
AU2023200265B2 (en) 2024-08-15
KR20210094138A (ko) 2021-07-28
RU2021111037A3 (enExample) 2022-02-10
RS62819B1 (sr) 2022-02-28
ES2902521T3 (es) 2022-03-28
PL3487851T3 (pl) 2022-04-11
JP2023089012A (ja) 2023-06-27
CN109641871B (zh) 2021-10-22
TW202220969A (zh) 2022-06-01
EP3487851B1 (en) 2021-10-20
TWI806385B (zh) 2023-06-21
KR20220021023A (ko) 2022-02-21
JP7030776B2 (ja) 2022-03-07
CY1124967T1 (el) 2023-01-05
EP3971177A1 (en) 2022-03-23
KR102667331B1 (ko) 2024-05-21
US20190161474A1 (en) 2019-05-30
AR109108A1 (es) 2018-10-31
CN114014844A (zh) 2022-02-08
EA202190285A1 (ru) 2021-08-31
SMT202400335T1 (it) 2024-09-16
KR20240155367A (ko) 2024-10-28
TW202134228A (zh) 2021-09-16
EP3487851A4 (en) 2019-12-25
HRP20211868T1 (hr) 2022-03-04
TWI851226B (zh) 2024-08-01
DK3971177T3 (da) 2024-07-15
AU2017298187A1 (en) 2018-12-20
CN109641871A (zh) 2019-04-16
MX2021014852A (es) 2022-01-18
US10947218B2 (en) 2021-03-16
AU2017298187B2 (en) 2019-11-14
AU2021201424C1 (en) 2023-02-02
RU2019104609A3 (enExample) 2020-09-30
HUE067992T2 (hu) 2024-12-28
PT3487851T (pt) 2022-01-07
US12466808B2 (en) 2025-11-11
US20200299265A1 (en) 2020-09-24
HRP20241015T1 (hr) 2024-11-08

Similar Documents

Publication Publication Date Title
TWI851226B (zh) 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
RU2826177C1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2
HK40117528A (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
HK40069664B (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
HK40069664A (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
EA049492B1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
HK40007022B (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
EA045493B1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2